These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 22585219)
1. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Felton TW; Hope WW; Lomaestro BM; Butterfield JM; Kwa AL; Drusano GL; Lodise TP Antimicrob Agents Chemother; 2012 Aug; 56(8):4087-94. PubMed ID: 22585219 [TBL] [Abstract][Full Text] [Related]
2. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Patel N; Scheetz MH; Drusano GL; Lodise TP Antimicrob Agents Chemother; 2010 Jan; 54(1):460-5. PubMed ID: 19858253 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050 [TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children. Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978 [TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009 [TBL] [Abstract][Full Text] [Related]
6. [Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion]. Lü Y; Yan Z; Wang DH; Dong WL; Yang Y; Xia R Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):479-83. PubMed ID: 24021044 [TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. Chen R; Qian Q; Sun MR; Qian CY; Zou SL; Wang ML; Wang LY Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):363-72. PubMed ID: 25894901 [TBL] [Abstract][Full Text] [Related]
8. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants. Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963 [TBL] [Abstract][Full Text] [Related]
10. Dose optimization of piperacillin/tazobactam in critically ill children. De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Landersdorfer CB; Bulitta JB; Kirkpatrick CM; Kinzig M; Holzgrabe U; Drusano GL; Stephan U; Sörgel F Antimicrob Agents Chemother; 2012 Nov; 56(11):5715-23. PubMed ID: 22908169 [TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations? Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823 [TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children. Thibault C; Lavigne J; Litalien C; Kassir N; Théorêt Y; Autmizguine J Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427292 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. Cies JJ; Shankar V; Schlichting C; Kuti JL Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417 [TBL] [Abstract][Full Text] [Related]
16. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study. Guet-Revillet H; Tomini E; Emirian A; Join-Lambert O; Lécuyer H; Zahar JR; Jullien V Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276 [TBL] [Abstract][Full Text] [Related]
17. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288 [TBL] [Abstract][Full Text] [Related]
18. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Kim A; Sutherland CA; Kuti JL; Nicolau DP Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458 [TBL] [Abstract][Full Text] [Related]
19. Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa. Zelenitsky S; Nash J; Weber Z; Iacovides H; Ariano R J Chemother; 2016 Oct; 28(5):390-4. PubMed ID: 27077931 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]